While the current criteria for defining Alzheimer’s disease (AD) primarily consider amyloid pathology, increasing evidence suggests that other key factors, such as cerebrovascular injury and neuroinflammation, also contribute to memory decline among older adults. We asked how white matter hyperintensities (WMH), vascular risk factors, and neuroinflammatory markers impact neurodegeneration and memory dysfunction in the context of aging and AD. Our goal is to enhance our understanding of these non-amyloid pathologies so that they can be integrated into mechanistic models of AD and influence future therapeutic interventions. My first study (Chapter 1) investigated whether WMH and medial temporal lobe (MTL) subregional volumes are linked to memory performance in older adults at risk for AD. I found that posterior WMH, in particular, were associated with hippocampal and rhinal cortical volumes, which in turn predicted memory performance. Importantly, the relationship between WMH and memory was fully mediated by perirhinal cortical volume, indicating that cerebrovascular injury may drive memory decline by exacerbating neurodegeneration in specific MTL subregions. These results were published in Rizvi et al. (2022).
In my second study (Chapter 2), I extended my investigation of cerebrovascular risk and pathology to a sample of older adults with Down syndrome (DS), a genetic condition that predisposes adults to AD. Interestingly, individuals with DS are less prone to hypertension but remain vulnerable to cerebrovascular injury. In this sample, I found that higher pulse pressure was associated with increased posterior WMH. Higher pulse pressure was also associated with dementia diagnosis, which was mediated by WMH and neurodegenerative changes. This work highlights the critical role of vascular health in cognitive outcomes for individuals with DS, even in the absence of classic hypertension. These results were published in Rizvi et al. (2024b).
In my third study (Chapter 3), I focused on upstream pathologies that may lead to cerebrovascular injury and dysfunction. In particular, I studied the role of neuroinflammation in AD, revealing two distinct pathways involving plasma markers YKL-40 and GFAP. YKL-40 was related to cerebrovascular injury, while GFAP was linked to amyloid-beta (Aβ) deposition. Both pathways converged on tau pathology, leading to MTL atrophy and memory deficits. These findings point to neuroinflammation as a key component of AD, and to the parallel and convergent pathways by which it impacts tau-mediated neurodegeneration and cognitive decline. These results have been submitted for publication and posted to bioRxiv (Rizvi et al., 2024a).
Collectively, these findings emphasize the critical contributions of vascular injury, vascular health, and neuroinflammation to neurodegeneration and memory loss in older adults. They suggest that both WMH and inflammatory markers are important predictors of AD-related cognitive decline, with implications for interventions to preserve brain health and mitigate memory impairment in at-risk populations.